AbbVie Inc. on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira.
Bayer predicted on Tuesday its experimental drug against dangerous blood clots could make more than 5 billion euros ($5.4 billion) in peak annual sales, as the company seeks to revive a share price that has drawn interest from activist investors.
BioNTech SE has agreed to acquire the British artificial intelligence (AI) startup InstaDeep for up to 562 million pounds ($682 million) to speed up its biotech research beyond COVID shots.
The American Academy of Pediatrics (AAP) on Monday recommended use of weight-loss drugs in children ages 12 years or older for treatment of obesity, which impacts about 14.4 million kids and adolescents in the United States and can lead to serious health complications.
Ocugen Inc. said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd. met the main goals of a trial in the United States.
The Omicron-adapted COVID-19 vaccine booster developed by Pfizer Inc. and BioNTech SE sharply reduced hospitalizations among older patients, Israeli researchers said on Monday, in some of the first evidence of the jab’s real-world effectiveness.
China is in talks with Pfizer Inc. to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm’s COVID-19 antiviral drug Paxlovid in China, three sources told Reuters.
Baxter International Inc. said on Friday it plans to spin off its kidney care units, becoming the latest medical device maker to slim down in the face of supply-chain challenges.
On Thursday, Fate Therapeutics announced it terminated a 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen. In response, the next-generation cell therapy company’s stock sank by 54% in pre-market trading Friday.
Biotech behemoth Amgen inked a licensing agreement Thursday with Netherlands-based Synaffix for the development of next-generation antibody-drug conjugates.
